Kampanjeplan Taysha Gene Therapies, Inc.
Avansert tidsplan
Enkel graf
Om selskapet Taysha Gene Therapies, Inc.
Компания Taysha Gene Therapies, Inc., занимающаяся генной терапией, специализируется на разработке и коммерциализации генной терапии на основе аденоассоциированных вирусов для лечения моногенных заболеваний центральной нервной системы. В первую очередь он разрабатывает TSHA-101 для лечения ганглиозидоза GM2; TSHA-118 для лечения болезни CLN1; и TSHA-102 для лечения синдрома Ретта. Taysha Gene Therapies, Inc. flere detaljer| IPO date | 2020-09-24 |
|---|---|
| ISIN | US8776191061 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.tayshagtx.com |
| Цена ао | 1.76 |
| Prisendring per dag: | -0.6536% (1.53) |
|---|---|
| Prisendring per uke: | -0.6536% (1.53) |
| Prisendring per måned: | -17.84% (1.85) |
| Prisendring over 3 måneder: | -23.62% (1.99) |
| Prisendring over seks måneder: | -32.44% (2.25) |
| Prisendring per år: | +2.7% (1.48) |
| Prisendring over 3 år: | -75.68% (6.25) |
| Prisendring over 5 år: | 0% (1.52) |
| Prisendring over 10 år: | 0% (1.52) |
| Prisendring siden begynnelsen av året: | -40.63% (2.56) |
|
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institusjoner | Volum | Dele, % |
|---|---|---|
| FMR, LLC | 22439124 | 12 |
| RA Capital Management, L.P. | 18472503 | 9.88 |
| RTW Investments LP | 16893185 | 9.03 |
| VR Adviser, LLC | 10412872 | 5.57 |
| Vanguard Group Inc | 6195567 | 3.31 |
| Avoro Capital Advisors LLC | 4355555 | 2.33 |
| Baker Brothers Advisors, LLC | 4004756 | 2.14 |
| Eversept Partners, LP | 3780714 | 2.02 |
| Tybourne Capital Management (HK) Limited | 3700000 | 1.98 |
| Artal Group S.A. | 3663104 | 1.96 |
| ETF | Dele, % | Lønnsomhet for året, % | Utbytte, % |
|---|---|---|---|
| iShares Neuroscience and Healthcare ETF | 0.6323 | 19.72 | 0.03 |
| Invesco Dorsey Wright Healthcare Momentum ETF | 0.45001 | 6.18 | 0.12263 |
| Virtus LifeSci Biotech Clinical Trials ETF | 0.40834 | 63.04 | 0.33 |
| iShares Micro-Cap ETF | 0.0939 | 17.09 | 1.54048 |
| Future Tech ETF | 0.04503 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.04503 | 618.5 | 0.8416 |
| Invesco Nasdaq Biotechnology ETF | 0.03944 | 28.58 | 0.8565 |
| Vanguard Russell 2000 Growth ETF | 0.03 | 23.05 | 0.60264 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.02925 | 31.36 | 1.41955 |
iShares Russell 2000 Growth ETF
|
0.02724 | 38.04 | 0.6026 |
| ProShares Ultra Nasdaq Biotechnology | 0.02673 | 51.7 | 0.85651 |
| Vanguard Russell 2000 ETF | 0.01 | 17.16 | 1.48801 |
ProShares UltraPro Russell2000
|
0.00743 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.0021 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.001 | 24.83 | 1.43482 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Veileder | Stillingstittel | Betaling | Fødselsår |
|---|---|---|---|
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 703.61k | 1978 (47 år) |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead | N/A | |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | N/A | |
| Mr. Sean P. Nolan | CEO & Chairman | 674k | 1968 (57 år) |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 619.1k | 1967 (58 år) |
| Mr. Sean McAuliffe | Chief Business Officer | N/A | |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | N/A | |
| Ms. Tracy M. Porter SPHR | Chief People Officer | N/A | |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | N/A | |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | N/A |
Adresse: United States, Dallas, TX , 3000 Pegasus Park Drive - åpne i Google maps, åpne Yandex-kart
Nettsted: http://www.tayshagtx.com
Nettsted: http://www.tayshagtx.com
